# Tislelizumab Combined with Mitoxantrone Hydrochloride Liposome in Extranodal Natural Killer/T Cell Lymphoma

> **NCT05464433** · PHASE1,PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Sun Yat-sen University** · enrollment: 46 (estimated)

## Conditions studied

- Extranodal Natural Killer T Cell Lymphoma

## Interventions

- **DRUG:** Tislelizumab combined with Liposomal mitoxantrone hydrochloride
- **DRUG:** Maintenance of tislelizumab

## Key facts

- **NCT ID:** NCT05464433
- **Lead sponsor:** Sun Yat-sen University
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2022-06-23
- **Primary completion:** 2025-04-30
- **Final completion:** 2025-11-30
- **Target enrollment:** 46 (ESTIMATED)
- **Last updated:** 2025-03-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05464433

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05464433, "Tislelizumab Combined with Mitoxantrone Hydrochloride Liposome in Extranodal Natural Killer/T Cell Lymphoma". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT05464433. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*